All posts by: MarksMan Healthcare

About MarksMan Healthcare

MarksMan Healthcare Communications

The healthcare industry is challenged with administrative and regulatory intricacies that make achieving the healthcare objectives, such as better patient outcomes and reduced costs, difficult. Difficulties faced while improving patient outcomes are predominantly taxing, since health systems measure and report thousands of outcomes annually. (1) In addition, healthcare industry is saturated with the need for improved quality […]

Traditionally, the pharmaceutical industry has always been dependent upon the ‘push’ strategy for successful market access for products. The drug approval process, involving submission of data on efficacy, safety, and tolerability to the regulatory agencies, used to be simple; which ended with the drug being marketed to the targeted physicians and dispensed by pharmacies post approval. Thus, this whole process involved a limited set of stakeholders, viz. physicians, regulatory agencies, and pharmacies.

Drug development is a challenging and time-consuming procedure. An unmet medical need is a condition, the cure or diagnosis of which is not being addressed effectively by currently available therapies. To meet such an unmet medical need and treat severe diseases, Fast Track approval process has been introduced by Food and Drug Administration (FDA), which […]

There is heaps-full of data existing in the healthcare domain that has been generated historically, by means of record keeping, compliance & regulatory requirements, and patient care. (1) The current trend suggests faster digitization of this large amount of data, known as ‘Big Data’, that have been stored as hard copies over time. Big Data […]

Currently, the data protection law in India is facing many issues due to the absence of proper legislative framework. The theft and sale of stolen data is happening across vast continents, where physical boundaries pose no restriction in today’s technologically advanced era. India, being the largest host of outsourced data processing in the world, could […]

Traditionally, the pharmaceutical industry has always been dependent upon the ‘push’ strategy for successful market access for products. The drug approval process, involving submission of data on efficacy, safety, and tolerability to the regulatory agencies, used to be simple; which ended with the drug being marketed to the targeted physicians and dispensed by pharmacies post approval. Thus, […]

Every country exercises strict control on medicines’ market access. Typically, this requires successful completion and adequate presentation of results from phase I through phase III clinical trials, bringing forward the findings of medicine’s safety and efficacy. The USFDA approves approximately 40 new medicines for the US market each year through this process. (1) In India, […]